We are live on
!
Find out more
SEC
Seven Eight Capital Portfolio holdings
AUM
$1.11B
1-Year Est. Return
29.48%
This Fund
S&P 500
This Quarter
Est. Return
-4.54%
1 Year Est. Return
+29.48%
3 Year Est. Return
+13.61%
5 Year Est. Return
+117.69%
10 Year Est. Return
+239.1%
AUM
$130M
AUM Growth
+$26.6M
(+26%)
Cap. Flow
+$34M
Cap. Flow
% of AUM
26.04%
Top 10 Holdings %
Top 10 Hldgs %
9.96%
Holding
800
New
284
Increased
141
Reduced
77
Closed
294
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sensata Technologies
ST
|
+$1.38M |
| 2 |
Mastercard
MA
|
+$1.33M |
| 3 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$1.33M |
| 4 |
Abbott
ABT
|
+$1.31M |
| 5 |
Universal Health Services
UHS
|
+$1.29M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$1.17M |
| 2 |
Teradata
TDC
|
+$1.08M |
| 3 |
Phillips 66
PSX
|
+$1.05M |
| 4 |
Marathon Petroleum
MPC
|
+$1.05M |
| 5 |
Pentair
PNR
|
+$1.05M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 15.22% |
| 2 | Financials | 13.03% |
| 3 | Industrials | 12.41% |
| 4 | Technology | 11.95% |
| 5 | Healthcare | 10.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Ambev
ABEV
$47.9B
| $98.6K | 0.08% |
+15,055
| New | +$106K |
|
327
Eastman Chemical
EMN
$7.69B
| $97.1K | 0.07% |
+1,200
| New | +$100K |
|
328
Xylem
XYL
$28.5B
| $96.4K | 0.07% |
2,715
+2,100
| +341% | +$78K |
|
329
Cheesecake Factory
CAKE
$5.03B
| $95.5K | 0.07% |
2,100
-13,300
| -86% | -$596K |
|
|
ACHN
330
DELISTED
Achillion Pharmaceuticals
ACHN
| $94.2K | 0.07% |
+9,443
| New | +$87.7K |
|
331
Popular Inc
BPOP
$11B
| $94.2K | 0.07% |
+3,200
| New | +$102K |
|
332
Canadian Natural Resources
CNQ
$96.9B
| $93.6K | 0.07% |
4,983
+4,758
| +2,115% | +$98.2K |
|
333
Incyte
INCY
$25.8B
| $93.2K | 0.07% |
+1,900
| New | +$95.3K |
|
334
Pediatrix Medical
MD
$2.2B
| $93.2K | 0.07% |
+1,700
| New | +$96.5K |
|
|
WUBA
335
DELISTED
58.com Inc
WUBA
| $93.1K | 0.07% |
2,500
-500
| -17% | -$23.1K |
|
336
Northrop Grumman
NOC
$76B
| $92.2K | 0.07% |
700
+500
| +250% | +$63.1K |
|
337
Procter & Gamble
PG
$340B
| $92.1K | 0.07% |
1,100
-12,300
| -92% | -$1.01M |
|
|
LM
338
DELISTED
Legg Mason, Inc.
LM
| $92.1K | 0.07% |
+1,800
| New | +$89.3K |
|
|
WBMD
339
DELISTED
WebMD Health Corp.
WBMD
| $92K | 0.07% |
2,200
+1,900
| +633% | +$91.7K |
|
|
NFX
340
DELISTED
Newfield Exploration
NFX
| $91.7K | 0.07% |
+2,475
| New | +$103K |
|
|
SEMG
341
DELISTED
SEMGROUP CORPORATION
SEMG
| $91.6K | 0.07% |
1,100
-1,100
| -50% | -$90.6K |
|
342
Commault Systems
CVLT
$4.98B
| $90.7K | 0.07% |
1,800
+501
| +39% | +$25.8K |
|
|
SN
343
DELISTED
Sanchez Energy Corporation
SN
| $89.3K | 0.07% |
+3,400
| New | +$108K |
|
344
Acadia Pharmaceuticals
ACAD
$4.51B
| $89.1K | 0.07% |
+3,600
| New | +$84.2K |
|
345
Cemex
CX
$16.9B
| $87.6K | 0.07% |
7,556
-4,274
| -36% | -$49.6K |
|
|
OCR
346
DELISTED
OMNICARE INC
OCR
| $87.2K | 0.07% |
1,400
-2,500
| -64% | -$159K |
|
|
HBI
347
DELISTED
Hanesbrands
HBI
| $86K | 0.07% |
+3,200
| New | +$81.3K |
|
|
BID
348
DELISTED
Sotheby's
BID
| $85.8K | 0.07% |
+2,403
| New | +$94.7K |
|
349
Marvell Technology
MRVL
$147B
| $85.1K | 0.07% |
6,315
-7,700
| -55% | -$106K |
|
|
JKS
350
JinkoSolar
JKS
$764M
| $83.3K | 0.06% |
3,030
+2,973
| +5,216% | +$84.8K |
|
Similar funds
PP
ECM
GCAC
CAM
D
GFS
FTIS
AIA
Seven Eight Capital's Q3 2014 Portfolio in Review
As of Q3 2014, Seven Eight Capital held 800 positions worth $130M, up 26% from $104M the previous quarter. Its ten largest holdings account for 10% of the portfolio.
Seven Eight Capital deployed $34M of net new capital in Q3 2014, opening 284 new positions and adding to 141 existing holdings. Its largest new stake was Sensata Technologies: 29,200 shares worth $1.3M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 15% of assets, up from 13% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Teradata, an estimated $1.08M trimmed.
- Seven Eight Capital's largest Q3 2014 buy was Sensata Technologies: 29,200 shares worth $1.3M.
- Seven Eight Capital added most to Medtronic in Q3 2014, an estimated $1.27M increase.
- Seven Eight Capital's biggest Q3 2014 reduction was Teradata, cutting an estimated $1.08M.
- Seven Eight Capital fully exited Allergan plc in Q3 2014, selling an estimated $1.17M.
- Seven Eight Capital's ten largest holdings make up 10% of its $130M portfolio in Q3 2014.
- Seven Eight Capital opened 284 new positions and closed 294 in Q3 2014.
- Seven Eight Capital's portfolio value rose 26% quarter-over-quarter to $130M.
Based on Seven Eight Capital's 13F filing for Q3 2014, filed 13 Nov 2014.